Hillsdale Investment Management Inc. Boosts Stock Position in Amneal Pharmaceuticals, Inc. $AMRX

Hillsdale Investment Management Inc. lifted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 89,403.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 716,029 shares of the company’s stock after buying an additional 715,229 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Amneal Pharmaceuticals were worth $7,167,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Exchange Traded Concepts LLC bought a new position in Amneal Pharmaceuticals during the third quarter valued at $31,000. Inceptionr LLC purchased a new position in shares of Amneal Pharmaceuticals during the 2nd quarter valued at $115,000. State of Tennessee Department of Treasury purchased a new position in shares of Amneal Pharmaceuticals during the 2nd quarter valued at $133,000. Whalen Wealth Management Inc. bought a new position in shares of Amneal Pharmaceuticals during the 2nd quarter worth $135,000. Finally, Truist Financial Corp purchased a new stake in Amneal Pharmaceuticals in the 3rd quarter worth about $137,000. Institutional investors own 31.82% of the company’s stock.

Analyst Ratings Changes

AMRX has been the topic of several recent research reports. Truist Financial set a $15.00 price objective on shares of Amneal Pharmaceuticals in a report on Wednesday, January 7th. Barclays began coverage on shares of Amneal Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $15.00 price target on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $13.00 price objective (up from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $13.80.

Amneal Pharmaceuticals Trading Down 0.7%

Shares of Amneal Pharmaceuticals stock opened at $14.50 on Friday. The company’s 50-day moving average price is $13.55 and its 200-day moving average price is $11.54. Amneal Pharmaceuticals, Inc. has a 12-month low of $6.68 and a 12-month high of $15.42. The company has a market cap of $4.56 billion, a price-to-earnings ratio of 725.36 and a beta of 1.36.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.